Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

5 Things to Consider When Launching a New Drug: MMIT Meet the Expert webinar recap on Predicting Payer Uptake with Precision

Posted by MMIT on Apr 15, 2021

new-blog-image-development-2

On April 6, MMIT kicked off a six-part Meet the Expert webinar series. The first session was focused on predicting payer uptake with precision. For example, many pharma manufacturers use analogs to predict payer uptake of a new drug being launched into the market. Tracking how an analog drug performed can help drug manufacturers improve messaging to payers, identify coverage challenges, and accurately predict payer uptake.

But choosing the right analogs can be challenging, said MMIT’s Carolyn Zele and Ritupriya Yamujala. Suppose the manufacturer’s drug is the first oral oncolytic for a particular tumor type. What criteria should the manufacturer consider in selecting an analog for comparison:

(1) Launch order. Where does the new drug fit into the market? Were there other drugs recently launched or will it be among the first? How many drugs have already been discussed by the payer’s Pharmacy & Therapeutics Committee in this class? For example, if the new therapy is the first launch in that category in a long time, the manufacturer should choose an analog that was also launched into a stable market.

(2) Clinical data. For a novel drug that had breakthrough therapy designation, it can be hard to find a drug with significantly similar clinical data. But you can look for an analog drug that is also novel and breakthrough and thus posed similar coverage considerations for a payer’s Pharmacy & Therapeutics Committee meeting.

(3) Pricing. How does the price of the new drug compare to the prices of the drugs already available? Is it going up against any rebate contracting? The manufacturer should select analogs that launched with a similar price differential or similar contracting availability.

(4) Physician preference or bias. Since this drug is the first oral in the market for a particular tumor type, the manufacturer may encounter physicians who are skeptical that an oral will work as well as the infused products and should find an analog that faced similar challenges.

(5) Market Share. What is the patient population taking today and is it working? Is the payer currently getting a rebate and what are the terms? Does the current rebate require preference? Is it based on clinical outcomes? If the payer decided to cover this drug, what would it mean for any current rebate agreements?

For more information about how MMIT can help you with launch predictability, contact us today at busdev@mmitnetwork.com.

To watch a replay of this webinar, visit www.mmitnetwork.com/meet-the-expert-predicting-payer-uptake.

And check out our webinar lineup here. The next session is on April 27 and the topic is Access Trends for Innovative Technology: Cell and Gene Therapies, Biomarkers and TeleMedicine.

Subscribe to the MMIT blog for more pharma, provider, and payer perspectives on key topics that affect the healthcare network.

Subscribe for Weekly Perspectives

Topics: Product Release, Payer, Branding & Marketing